SUPN - CIK 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $47.33M | $171.95M | $111.08M | $116.83M | $127.13M | $138.40M |
| Capital expenditure | $1.34M | $725.00K | $551.00K | $412.00K | - | $3.45M |
| Investing cash flow | $4.11M | -$189.87M | $268.73M | -$216.66M | -$81.91M | -$34.70M |
| Dividends paid | - | - | - | - | - | - |
SUPERNUS PHARMACEUTICALS, INC. reported operating cash flow of $47.33M for fiscal year 2025. That is down 72.5% from $171.95M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $66.81M (FY 2016) to $47.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $9.13M | $12.19M | -$397.88M | -$10.48M | -$130.42M | $3.56M |